SCHEMBL26062077

SCHEMBL26062077

CC(=O)C1(CCCCCc2ccccc2CCCCCC2(C(=O)O)CC2)CC1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BID P55957 4/20 0.35
MCL1 Q07820 4/20 0.35
BCL2L1 Q07817 3/20 0.35
BAK1 Q16611 3/20 0.35
KAT8 Q9H7Z6 2/20 0.35
PPARG P37231 2/20 0.35
PPARA Q07869 2/20 0.35
EP300 Q09472 1/20 0.35
KAT2A Q92830 1/20 0.35
KAT2B Q92831 1/20 0.35
KAT5 Q92993 1/20 0.35
SAE1 Q9UBE0 1/20 0.35
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35
CYSLTR2 Q9NS75 4/20 0.35
CYSLTR1 Q9Y271 4/20 0.35
LIPG Q9Y5X9 1/20 0.34
TBXAS1 P24557 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25997246 1.00 BID (0.35) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL25997249 1.00 BID (0.35) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL26062073 1.00 BID (0.35) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL25997257 1.00 BID (0.35) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL26062074 1.00 BID (0.35) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL26062066 0.98 CYP4F2 (0.35) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL25997236 0.94 ALDH1A1 (0.34) CYP4F2CYP4A11
SCHEMBL26062075 0.94 CYP4F2 (0.38) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL25997261 0.94 CYP4F2 (0.38) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL25997251 0.94 CYP4F2 (0.38) BIDMCL1BCL2L1BAK1KAT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11737995-B2 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease ESPERVITA THERAPEUTICS, INC. (US) 2023-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11737995-B2 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease AHR, PKD1, CFTR BID 424/4885MCL1 4164/4885BCL2L1 4083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.